
4DMedical is scaling its lung-imaging software portfolio, led by CT:VQ, across hospitals and imaging networks. FY26 scan volumes rose 77% to 344,075, while cash reached A$278m; however, the company remains loss-making as it pursues commercial adoption and revenue growth.

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.

4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.